STAT

MARCH 15, 2023

After two years as host of the “First Opinion Podcast” and many more as the founding editor of STAT’s expansive, authoritative First Opinion platform, Pat Skerrett put down his editing pen and microphone to start a new chapter — retirement. Read the rest…

94

94

STAT

FEBRUARY 10, 2024

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay.

FDA 107

FDA 107

Pharmaceutical Technology

FEBRUARY 26, 2024

Merck's KEYTRUDA has received a positive opinion from the EMA CHMP for use in combination with chemotherapy for non-small cell lung cancer.

Chemotherapy 104

Chemotherapy 104

STAT

DECEMBER 9, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay.

107

107

STAT

FEBRUARY 17, 2024

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay. “ Dental care is in crisis.

100

100

STAT

DECEMBER 29, 2022

The 22nd year of the 21st century, like most years before it, had its share of turbulence, offering opinion/perspective authors a wealth of topics to write about.

Medical Records 98

Medical Records 98

STAT

JANUARY 6, 2024

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay.

109

109

STAT

AUGUST 16, 2023

First Opinion , STAT’s platform for opinion and perspective essays, welcomes submissions about the biopharma industry, medical science and health care, and other topics related to the life sciences writ large. Here are general guidelines for submissions: Read the rest…

95

95

STAT

DECEMBER 23, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay.

FDA 102

FDA 102

STAT

JANUARY 13, 2024

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay. “ Pumping milk at JPM was a nightmare.

Insurance 101

Insurance 101

STAT

DECEMBER 2, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor  here , or find the submission form at the end of any First Opinion essay.

109

109

STAT

DECEMBER 16, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay. “ U.S.

Medical Schools 102

Medical Schools 102

STAT

NOVEMBER 16, 2022

In a special event as part of STAT’s Open Doors initiative, the “First Opinion Podcast” was recorded live this week in front of an audience with returning guest Jay Baruch.

97

97

PharmExec

OCTOBER 13, 2023

Industry experts discuss the relationship between digital and traditional (key) opinion leaders and how companies are adjusting their strategies to harness the unique brand engagement benefits each role can provide in driving better patient outcomes.

119

119

European Pharmaceutical Review

FEBRUARY 24, 2023

The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of ruxolitinib cream (Opzelura ) for non-segmental vitiligo with facial involvement in people over 12 years old. News : @EMA_News has issued a positive opinion for an Incyte-discovered therapy for patients with #vitiligo.

FDA 102

FDA 102

Fierce Healthcare

APRIL 19, 2024

Payers face a multifaceted challenge of managing rising healthcare costs while also meeting the heightened expectations of consumers who expect medical interactions to be as personalized and conven | Third-party analyses recently commissioned by The Clinic by Cleveland Clinic showed medical cost savings from, and high consumer interest in, virtual (..)

52

52

STAT

NOVEMBER 18, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay.

102

102

European Pharmaceutical Review

APRIL 6, 2023

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EPYSQLI , a biosimilar referencing Soliris (eculizumab), also known as SB12. The post Eculizumab biosimilar gets positive CHMP opinion appeared first on European Pharmaceutical Review.

94

94

STAT

NOVEMBER 15, 2023

This week on the “First Opinion Podcast,” medical student Amelia Mercado and her professor J. But despite an increased awareness of mental health on campuses across the country, there are still barriers keeping many students from accessing the care that they need.

Insurance 117

Insurance Medical Schools 117

Outsourcing Pharma

OCTOBER 9, 2023

Calliditas Therapeutics AB announced on Friday (October 5) that the European Medicines Agency (EMA) has issued a positive opinion on the companyâs drug, setanaxib in Alport Syndrome (AS).

89

89

STAT

OCTOBER 10, 2023

This article is part of a partnership between First Opinion and Tradeoffs, a podcast exploring our confusing, costly, and often counterintuitive health care system. To

Insurance 114

Insurance 114

STAT

JUNE 28, 2023

On the latest episode of the “First Opinion Podcast,” oncologist Kristen Rice explains that drug shortages have been happening for several years but have been progressively worsening in the past few months. Drug shortages are a growing problem in the U.S.,

100

100

STAT

APRIL 14, 2024

As diligent taxpayers breathe a sigh of relief that the hassle of filing their tax forms is over for another year, the Internal Revenue Service continues to let most U.S. hospitals pay nothing in federal taxes. It’s time for Congress to take a hard look at the IRS’s hand in health care.

Hospitals 145

Hospitals 145

STAT

APRIL 16, 2024

The face of autism was once predominantly white. The Centers for Disease Control and Prevention reported last year that the prevalence of autism across all racial and ethnic groups is reaching parity.

136

136

STAT

NOVEMBER 17, 2023

This article is part of a partnership between First Opinion and Tradeoffs, a nonprofit news organization exploring our confusing, costly, and often counterintuitive health care system. To

Hospitals 119

Hospitals 119

STAT

MARCH 1, 2023

Department of Health and Human Services has for decades ignored its responsibility to enforce civil rights laws, as I argued last year in a First Opinion essay.

Hospitals 96

Hospitals 96

pharmaphorum

JANUARY 8, 2024

Understanding the role of key opinion leaders in the digital landscape is crucial for effective communication strategies. Learn how to identify and engage with opinion leaders, fostering authenticity and leveraging their authority to unlock success in your industry.

Communication 52

Communication 52

pharmaphorum

APRIL 19, 2022

Typically, these key opinion leaders (KOLs) are researchers, physicians, or other healthcare providers (HCPs) that hold high levels of expertise in their respective fields. However, as the industry moves to occupy more virtual spaces, a new breed of industry influencers has emerged – digital opinion leaders (DOLs). Whitepaper download.

98

98

Pharmaceutical Technology

FEBRUARY 23, 2024

The positive opinion is based on findings from the Phase III COMMANDS trial which met its primary endpoint.

52

52

STAT

JULY 25, 2023

A STAT Report released Tuesday, “ Patients speak out: learning about health care first-person ,” brings those voices to readers in a collection of essays originally published as First Opinion columns.    Read the rest…

89

89

STAT

APRIL 5, 2024

When Francis Collins, then-director of the National Human Genome Research Institute, testified before Congress in 2003 about the significance of sequencing the human genome that year, he introduced personalized medicine as a new concept.

127

127

Pharmafile

NOVEMBER 13, 2023

The drug has gained this positive opinion for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with moderate to […] The post GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment appeared first on Pharmafile.

59

59

Pharmaceutical Technology

NOVEMBER 13, 2023

The EMA CHMP provided a positive opinion for granting approval to Merck’s Keytruda combination therapy to treat biliary tract cancer.

59

59

STAT

MAY 24, 2023

As Sanjay Basu wrote in a recent First Opinion, hospitals are using so-called “screen and refer” systems to identify people with social needs, like those who are experiencing domestic violence or hunger. But that frustrating experience is made even worse by a new trend in health care.

Hospitals 96

Hospitals 96

STAT

JULY 18, 2023

As people become increasingly familiar with artificial intelligence platforms like ChatGPT, it’s only a matter of time before patients turn to these tools in search of a diagnosis or second opinion. Change is already on the horizon.

Insurance 98

Insurance Hospitals 98

STAT

APRIL 23, 2024

The Food and Drug Administration’s accelerated approval program aims to speed “approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint” of overall survival (progression-free survival).

FDA 110

FDA 110

STAT

APRIL 17, 2024

When my son Conall took his life at age 17, it was devastating to me and our entire family. Conall was a caring, empathetic, and bright young man, but he had also struggled for many years with anxiety and depression. Like many kids his age, much of his life revolved around social media.

139

139